Stockreport

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Werewolf Therapeutics, Inc.  (HOWL) 
PDF – Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC Annual Meeting – – [Read more]